DataMeds AI Reports Q2 Revenue Beat, $18.4M Loss, and $6.5M Funding
MEDS sits 20% above its 52-week low of $1.255.
Summary
DataMeds AI reported Q2 revenue of $1.779M, up 14% sequentially, but a net operating loss of $18.4M. The company raised $6.5M in new funding and restructured $14.5M of debt, while lock-up agreements cover ~49% of shares outstanding.
Key Events · Earnings and Guidance · MEDS
-
Q2 Revenue Beat
Revenue grew 14% sequentially to $1.779M, exceeding management projections, but gross profit was only $182K.
-
Large Operating Loss
Net operating loss of $18.4M in Q2 2026, driven by an $8.9M loss on extinguishment of debt and higher G&A expenses.
-
New Funding and Debt Restructuring
Raised $6.5M in June 2026 and restructured $14.5M of pre-existing debt to provide a path to preferred equity swap.
-
Lock-Up Agreements
Holders of 1,533,930 common shares (~49% of shares outstanding) entered into lock-up agreements for at least 90 days.
Analysis · MEDS · Trade & Services
DataMeds AI's Q2 revenue grew 14% sequentially to $1.779M, beating management projections, but the company still posted a net operating loss of $18.4M, largely due to an $8.9M loss on debt extinguishment. The company raised $6.5M in June and restructured $14.5M of debt, providing runway for its turnaround. The upcoming Health Lives Here app launch with NFL Alumni Health in September is a key milestone, and lock-up agreements covering ~49% of shares outstanding reduce near-term selling pressure. However, the company remains in a precarious financial position with a stockholders' deficit of $19.5M and ongoing Nasdaq delisting risk.
At the time of this filing, MEDS was trading at $1.50 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $1.26 to $97.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.